IP Library Granted Patent US 11,166,972
Granted Patent B2
US 11,166,972 · App. 16/064,922 · Granted Nov 9, 2021

Compositions comprising nicotinamide riboside and a urolithin

Inventors: Penelope Andreux (Eclepens, CH); Christopher L. Rinsch (Morges, CH)
Assignee: Amazentis SA
A61K31/706A23L29/00A23L33/10A61K9/0053A61K31/366A61P21/00A61P25/28A23V2002/00A23V2200/316A23V2200/322A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,166,972
App. No.
16/064,922
Granted
Nov 9, 2021
Kind
B2
Abstract

Disclosed are compositions comprising nicotinamide riboside and a urolithin. The compositions are useful as medicaments, for example, for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases, and as dietary supplements, functional foods and beverages, and as specialized nutrition or medical foods.

Claims (15)

1. A composition comprising: nicotinamide riboside, and urolithin A or a salt thereof; wherein nicotinamide riboside is present in an amount of 20 mg to 5 g; and urolithin A is present in an amount of 10 mg to 5 g.

2. The composition of claim 1 , wherein the composition is formulated as a solid, a semi-solid, a powder, or a liquid.

3. The composition of claim 1 wherein the composition is formulated as a medicament, dietary supplement, functional food, functional beverage, specialised nutrition, or medical food.

4. The composition of claim 3 , wherein the composition is formulated as a medicament.

5. A method of treating a muscle-related pathological condition, a neurodegenerative disease, or a mitochondrial disease, comprising administering to a subject in need thereof an effective amount of a composition of claim 1 .

6. The method of claim 5 , wherein the muscle-related pathological condition is selected from musculoskeletal diseases or disorders, muscle wasting, myopathies, neuromuscular diseases, inclusion body myositis, Duchenne muscular dystrophy, sarcopenia, muscle atrophy, and cachexia.

7. A method of maintaining, preventing the decline of, or enhancing muscle or physical performance, comprising administering to a subject in need thereof an effective amount of a composition of claim 1 .

8. The method of claim 7 , wherein the subject suffers from age-related decline in muscle function, sarcopenia, age-related muscle wasting, sarcopenic obesity, physical fatigue, muscle fatigue, age-related swallowing difficulties, or dysphagia.

9. The method of claim 8 , wherein the subject is frail, pre-frail, or sedentary.

10. The method of claim 6 , wherein the dystrophy is Duchenne muscular dystrophy.

11. The method of claim 5 , wherein the composition is administered as a food product, food additive, food ingredient, functional food, medical food, dietary supplement, nutraceutical, nutritional supplement or oral preparation.

12. The method of claim 5 , wherein the neurodegenerative disease is Alzheimer's disease or Parkinson's disease.

13. A method of enhancing muscle function, comprising administering to a subject in need thereof an effective amount of a composition of claim 1 .

14. The method of claim 13 , wherein the composition is administered as a food product, food additive, food ingredient, functional food, medical food, dietary supplement, nutraceutical, nutritional supplement or oral preparation.

15. A method of increasing muscle mass or muscle growth, comprising administering to a subject an effective amount of a composition of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: ANDREUX, PENELOPE; RINSCH, CHRISTOPHER L.
To: AMAZENTIS SA
Reel/Frame 047948/0279 →
Priority Claims (2)
GB 1522892 · Dec 24, 2015 · national
GB 1611960 · Jul 8, 2016 · national
Continuity (1)
Related Publication 20190008883A1 · Jan 10, 2019
Cited By (7)
US 12,220,424 US 12,351,567 US 12,358,884 US 12,473,269 US 12,544,358 US 12,576,064 US 12,576,065